The Evaluation of NETs, Caspase-1 and Cytokines in ARDS Patients

Sponsor

Xiangya Hospital of Central South University (Other)

Overall Status

Unknown status

CT.gov ID

NCT03227107

Collaborator

National Natural Science Foundation of China (Other)

100

Enrollment

Location

Anticipated Duration (Months)

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

enrollment criteria and clinical data collection: follow the principles of medical ethics, the development of inclusion and exclusion criteria, select 90 cases of ARDS patients, in the active treatment at the same time, according to the Berlin standard severity of the disease divided into mild group, moderate Group and severe group, according to the prognosis during hospitalization is divided into survival group and death group. BALF specimens were collected on the day of admission to detect the levels of NETs and alveolar macrophages. The acute and chronic health status scoring system Ⅱ (APACHEⅡ) and Murray acute lung injury score, blood routine, creatinine, urea nitrogen, fasting blood glucose, Item, mean arterial pressure, arterial blood gas analysis, oxygenation index; record the patient's mechanical ventilation time and other data;
Pearson linear correlation analysis of BALF in the content of NETs, alveolar macrophage coke death level was a positive correlation between the Spearman rank correlation analysis BALF in the NETs content and alveolar macrophage coke death level, APACHE Ⅱ, Murray score, creatinine, Urea nitrogen, fasting blood glucose and other indicators and ARDS severity was positively correlated;
To analyze the prognostic factors of different prognostic factors, to evaluate the content of NETs in BALF, the level of alveolar macrophage coke, APACHEⅡ and Murray scores were analyzed by receiver operator characteristic curve (ROC curve) Short - term survival outcome prognostic value.

Condition or Disease	Intervention/Treatment	Phase
ARDS

Study Design

Study Type:

Observational

Anticipated Enrollment :

100 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

IRF-1 Regulate Alveolar Macrophage Pyroptosis in Acute Lung Injury and of Which Will be Possible Mechanism

Actual Study Start Date :

Jan 1, 2016

Anticipated Primary Completion Date :

Dec 30, 2020

Anticipated Study Completion Date :

Dec 30, 2020

Outcome Measures

Primary Outcome Measures

neutrophil extracellular traps, caspase-1,cytokines measurement [4 years]
Assessments with neutrophil extracellular traps be presented in ng/ml; Assessments with caspase-1 and cytokines be presented in pg/ml

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

ARDS patients diagnosis within 3 days
Over 18 years old but no more than 75 years old

Exclusion Criteria:

Severe thoracic open trauma
Pulmonary embolism
Severe cardiovascular and cerebrovascular disease
Endocrine system diseases
Coagulation dysfunction
Liver and kidney failure
Malignant tumors
Cardiogenic pulmonary edema

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Xiangya hospital of Central South University	Changsha	Hunan	China	410008

Sponsors and Collaborators

Xiangya Hospital of Central South University
National Natural Science Foundation of China

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

panpinhua, vice director of department of respiratory, Xiangya Hospital of Central South University

ClinicalTrials.gov Identifier:

NCT03227107

Other Study ID Numbers:

81470266

First Posted:

Jul 24, 2017

Last Update Posted:

Jul 24, 2017

Last Verified:

Jul 1, 2017

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD:

Undecided

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Study Results

No Results Posted as of Jul 24, 2017